Article: P.03 Extending the functional redundant cooperative miRNA tumour suppressor and oncogene network in T-ALL

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma